< Back to latest news & events

Blogs

New Blog Series – Agritech Thymes: A brief look at public prior use of plants in the US

July 2024

In the US, plants can be protected by utility patents, plant patents and/or plant variety rights. Both types of patent are subject to the same novelty rules of USC §102, which states that public prior use counts as a disclosure which can destroy the novelty of an invention.

In a decision from the Federal Circuit in the US in 2023 relating to a utility patent application on a particular plant variety, it was held that merely having a new plant variety on display to the public and labelled with its variety name before the filing date is a citeable public prior use of the plant.

This case1 related to the US utility patent for a variety of Calibrachoa plant named ‘Cherry Star’ having a distinctive star pattern on the petals. Claim 1 defined the variety by said pattern as follows:

A Calibrachoa plant comprising at least one inflorescence with a radially symmetric pattern along the center of the fused petal margins wherein said pattern extends from the center of the inflorescence and does not fade during the life of the inflorescences, and wherein the Calibrachoa plant comprises a single half-dominant gene, as found in Calibrachoa variety ‘Cherry Star,’ representative seed having been deposited under ATCC Accession No. PTA-13363’.

The applicant sought a reissue of the patent, and during the examination process of said reissue application, they disclosed that the variety had been had displayed at a Home Depot store event, where the public were able to view it. The applicant argued that the novelty was not destroyed by displaying the plant because the public did not have possession of the genetics of the plant to enable it to be bred, and were not aware that Cherry Star was the result of a “single half-dominant gene” as claimed. The PTAB examined “whether the purposed use: (1) was accessible to the public; or (2) was commercially exploited”, and held that although the variety wasn’t sold or analysed by the public, because the intended use of the plant variety is ornamental and its petal pattern was seen, that this was a citeable disclosure.

The federal circuit have only once before considered prior use in the context of plants, back in 2015. This earlier US decision2 related to two plant patents for ‘Scarlet Royal’ and ‘Autumn King’ table grapes in which the variety was grown in public before filing, but in this case, the variety was not identified and the intended use of the plant was for consumption rather than ornamental. The court confirmed that the “grape varieties cannot be reliably identified simply by viewing the growing vines alone.” As such in that case, the disclosure was not deemed to be novelty-destroying. It seems that perhaps if the cherry star was not identified as such by the labelling, their case may have been stronger. Furthermore, it seems that arguments could have been presented around the feature of the claim that the pattern ‘does not fade’ which would not have been made available to the public at the short event.

This case somewhat surprisingly shows that in situations where the use of the invention, even under a utility patent, is one of an aesthetic or visual nature then displaying it can be enough to destroy novelty by prior use in the US. A reminder that patent applications should always be filed before disclosure, and relying on technical genetic features of plant claims may not be enough to ensure novelty over prior use.


This article was prepared by Partners Punita Shah and Ellie Purnell.

Latest updates

Welcome to HGF Presents - New Video Series

Introducing HGF Presents a new video series delivering practical insights into European Patent Law and practice. Curated by our leading experts in chemistry, life sciences, technology & engineering, each concise …

Read article

Seminar on Incorporating Trade Secrets into your IP Strategy

HGF is hosting a Seminar on Incorporating Trade Secrets into your IP Strategy which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 10th …

Read article

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

Providing Enabling Disclosure for AI inventions at the EPO

  Video overview: The equivalent to the enablement requirement in the US at the EPO is Sufficiency. There is an increasing trend for the sufficiency of AI related patent applications …

Read article

Personalised Medicine Patenting of Known Drugs for Known Indications at the EPO

Video overview: The identification of specific sub-groups of patients to treat with a known drug, even if said patients may have been treated before with the drug, can yield patentable …

Read article

Novelty Over Clinical Trials at the EPO

Video overview: Second medical use claims can be novel over clinical trials in European patents. Typically, such a claim would be fairly narrow, e.g. perhaps mapping onto specific indications and …

Read article

Regulatory Exclusivity for
Medicinal Products in Europe

Video overview: New Medical Products 8 years of data exclusivity, followed by 2 years of market exclusivity. +1 year market exclusivity possible for a new indication showing significant clinical benefit. No exclusivity granted for new formulations or routes of …

Read article

Added Matter - Part 2

Video overview: Pre and Post-Grant Amendments are governed by Articles 123(2) & 123(3) EPC respectively Before grant, amendments can broaden the claim scope as long as the resulting claim is …

Read article